阿诺医药宣布,其针对携带Ras基因突变的实体瘤研发的广谱Ras抑制剂AN9025,已在全球范围内启动I期临床试验,并完成首例患者入组。该试验旨在评估AN9025在晚期实体瘤患者中的安全性、耐受性及初步疗效。
阿诺医药宣布,其针对携带Ras基因突变的实体瘤研发的广谱Ras抑制剂AN9025,已在全球范围内启动I期临床试验,并完成首例患者入组。该试验旨在评估AN9025在晚期实体瘤患者中的安全性、耐受性及初步疗效。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.